8-K
filed November 7, 2023, 6:59 PM ET
ticker GMED
CIK 0001237831
earnings
confidence high
sentiment positive
materiality 0.70
Globus Medical Q3 revenue $383.6M (+51% YoY); raises FY revenue guidance to $1.55B
GLOBUS MEDICAL INC
2023-Q3 EPS reported
$0.98
revenue$951,942,000
- GAAP net income $1.0M, diluted EPS $0.01; non-GAAP diluted EPS $0.57 (+14.7% YoY).
- NuVasive merger closed Sept 1; combined results from that date drove 51% revenue increase.
- Stand-alone Globus Medical net sales $281.2M (+10.7% YoY); U.S. +8.1%, International +25.5%.
- Non-GAAP adjusted EBITDA $112.9M (29.4% of sales); free cash flow $29.0M.
- FY 2023 revenue guidance raised to $1.55B (from $1.125B); non-GAAP EPS reaffirmed at $2.30.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
GLOBUS MEDICAL INC reported the quarter ended September 30, 2023 results: revenue $383.6 million, net income $1.0 million, EPS $0.01.
- Period
- the quarter ended September 30, 2023
- Revenue
- $383.6 million
- Net income
- $1.0 million
- EPS
- $0.01
- Result
- reported results
Exact text from the filing
merger with NuVasive, Inc. was completed on September 1, 2023 and results presented within include NuVasive, Inc. results from that closing date . · Worldwide net sales were $ 383.6 million , an increase of 5 1.0 % . · GAAP net income for the quarter was $ 1.0 million · GAAP d iluted earnings per share (“ EPS ”) was $0. 0 1 and non-GAAP diluted EPS was $0. 57 ·
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
GLOBUS MEDICAL INC reported full year fiscal 2023 results: revenue $1.55 billion, EPS $2.30. Guidance raised.
- Period
- full year fiscal 2023
- Revenue
- $1.55 billion
- EPS
- $2.30
- Guidance
- raised
- Result
- guidance update
Exact text from the filing
The Company today increased its full year fiscal 2023 revenue guidance to $1.55 billion, up from $1.125 billion, and reaffirmed non-GAAP fully diluted earnings per share guidance of $2.30.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.